Pulling an application is SOP in the EU when regulators have concluded that a rejection is imminent. Given today’s news and the rejection of Semuloparin by an FDA advisory panel in June (#msg-76811758), it’s reasonable to presume that this drug is effectively dead.
Semuloparin, an ultra-LMW heparin, is also knows as Mulsevo, Visamerin, and AVE5026. It was once touted as SNY’s follow-on product to Lovenox.